MedPath

Study of the Elevate Anterior and Apical Prolapse Repair System Compared to Native Tissue Repair for Pelvic Organ Prolapse

Phase 4
Terminated
Conditions
Pelvic Organ Prolapse
Interventions
Device: Elevate Anterior and Apical
Procedure: Native Tissue Repair for pelvic organ prolapse
Registration Number
NCT02121977
Lead Sponsor
ASTORA Women's Health
Brief Summary

The aim of this study is to further evaluate the safety and efficacy of the Elevate® Anterior and Apical Prolapse Repair System for repair of anterior/apical pelvic organ prolapse in a controlled, post-market cohort study.

Detailed Description

The Embrace 522 study has been terminated due to the closing of the Astora Women's Health business. No other entity will be taking responsibility for this study. The study was terminated with partial subject enrollment complete and therefore no primary or secondary data analysis can be performed. The data from this study resides in a national data base which Astora no longer has access and therefore is another reason why no data analysis can be performed. The national database is owned and managed by the American Urogynecology Society (AUGS). AUGS has access to Astora's data and will at some time in the near future publish results to physicians who are active participants in the registry. Full public disclosure of this data may not occur for a number of years and will be aggregated with data from other study sponsors.

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
285
Inclusion Criteria

Subject is female Subject is at least 18 years of age

Subject must have documented diagnosis of anterior or anterior and apical vaginal prolapse with leading edge of pelvic organ prolapse at or beyond the hymen. At or beyond the hymen is defined as POP-Q scores of Ba ≥ 0; or Ba ≥ 0 and C ≥ -1/2 TVL (for a multi-compartment anterior prolapse that includes the apical compartment)

Subject reports a bothersome bulge they can see or feel per PFDI-20, question 3, response of 2 or higher (i.e., responses of "somewhat", "moderately", or "quite a bit")

Subject or subject's legally authorized representative is willing to provide written informed consent

Subject is willing and able to comply with the follow-up regimen

Exclusion Criteria

Subject is pregnant or intends to become pregnant during the study

Subject has an active or chronic systemic infection including any gynecologic infection, untreated urinary tract infection (UTI) or tissue necrosis Subject has history of pelvic organ cancer (e.g. uterine, ovarian, bladder, or cervical)

Subject has history of pelvic organ cancer (e.g. uterine, ovarian, bladder, or cervical)

Subject has had prior or is currently undergoing radiation, laser therapy, or chemotherapy in the pelvic area

Subject has taken systemic steroids (within the last month), or immunosuppressive or immunomodulatory treatment (within the last 3 months)

Subject has systemic connective tissue disease (e.g. scleroderma, systemic lupus erythematosus (SLE), Marfan's syndrome, Ehlers Danhlos, collagenosis, polymyositis or polymyalgia rheumatica)

Subject has chronic systemic pain that includes the pelvic area or chronic focal pain that involves the pelvis

Subject has uncontrolled diabetes mellitus (DM)

Subject has a known neurologic or medical condition affecting bladder function (e.g., multiple sclerosis, spinal cord injury or stroke with residual neurologic deficit)

Subject is seeking obliterative vaginal surgery as treatment for pelvic organ prolapse (colpocleisis)

Subject is not able to conform to the modified dorsal lithotomy position

Subject is currently participating in or plans to participate in another device or drug study during this study

Subject has a known sensitivity to polypropylene

Subject has had previous prolapse repair with mesh in the target compartment

Subject is planning to undergo a concomitant repair with use of mesh in the non-target compartment

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Elevate Anterior and ApicalElevate Anterior and ApicalProlapse repair with mesh
Native Tissue RepairNative Tissue Repair for pelvic organ prolapseProlapse repair with sutures
Primary Outcome Measures
NameTimeMethod
Rate of device or procedure related serious adverse events36 months
Surgical success or failure through composite endpoint including anatomic, subjective and re-treatment measures36 months
Secondary Outcome Measures
NameTimeMethod
Changes in Quality of Life measured through the following questionaires: PFDI-20,PFIQ-7, PISQ-1236 months
Surgical success or failure through composite endpoint including anatomic, subjective and re-treatment measures36 months
Rate of repeat surgery/revision for prolapse arising from the same site/target compartment36 months

Trial Locations

Locations (31)

Cedars-Sinai Medical Group

🇺🇸

Beverly Hills, California, United States

National Center for Advanced Pelvic Surgery

🇺🇸

Washington, District of Columbia, United States

Urological Associates of Southern Arizona

🇺🇸

Tucson, Arizona, United States

Yale School of Medicine

🇺🇸

New Haven, Connecticut, United States

East Coast Institute for Research, LLC

🇺🇸

Jacksonville, Florida, United States

Chesapeake Urology

🇺🇸

Owings Mills, Maryland, United States

Adult & Pediatric Urology and Urogynecology

🇺🇸

Omaha, Nebraska, United States

Athena Women's Institute for Pelvic Health

🇺🇸

Turnersville, New Jersey, United States

Urogynecology & Pelvic Reconstructive Surgery - Atlantic Health System

🇺🇸

Morristown, New Jersey, United States

Premier Medical Group

🇺🇸

Poughkeepsie, New York, United States

The Center for Specialized Women's Health

🇺🇸

Whippany, New Jersey, United States

Seven Hills Woman's Health Center

🇺🇸

Cincinnati,, Ohio, United States

The Christ Hospital

🇺🇸

West Chester, Ohio, United States

Center for Women's Health of Lansdale

🇺🇸

Lansdale, Pennsylvania, United States

Swan Urogynecology

🇺🇸

Nashville, Tennessee, United States

The Female Pelvic Health Center

🇺🇸

Newtown, Pennsylvania, United States

Female Pelvic Medicine Institute of Virginia

🇺🇸

North Chesterfield, Virginia, United States

Athena Women's Health

🇺🇸

Issaquah, Washington, United States

The Clark Center for Urogynecology

🇺🇸

Newport Beach, California, United States

Women's Health Advantage

🇺🇸

Fort Wayne, Indiana, United States

Princeton Medical Center

🇺🇸

Princeton, New Jersey, United States

Weinberg Center for Women's Health and Medicine

🇺🇸

Baltimore, Maryland, United States

Beaumont Health System

🇺🇸

Royal Oak, Michigan, United States

Metro Urology

🇺🇸

Woodbury, Minnesota, United States

North Shore Women's Health Clinic

🇺🇸

Great Neck, New York, United States

The Institute for Female Pelvic Medicine - St. Luke's Hospital

🇺🇸

Allentown, Pennsylvania, United States

University of Texas at Galveston

🇺🇸

Galveston, Texas, United States

Lone Star Urogynecology and Continence Center

🇺🇸

Round Rock, Texas, United States

University of Washington Pelvic Health Center

🇺🇸

Seattle, Washington, United States

Urology of Virginia, PLLC

🇺🇸

Virginia Beach, Virginia, United States

Women's Cancer Center of Nevada

🇺🇸

Las Vegas, Nevada, United States

© Copyright 2025. All Rights Reserved by MedPath